Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

NCT00667420 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Closed due to slow accrual

Conditions

Esophageal Adenocarcinoma
Gastric Adenocarcinoma

Interventions

DRUG: panitumumab, epirubicin, oxaliplatin, xeloda

Sponsor

Massachusetts General Hospital